Pharmacokinetic sampling
Sponsors
RFS Pharma, LLC, University of North Carolina, Chapel Hill, University of Miami, AstraZeneca, Centre Hospitalier Universitaire de Nice
Conditions
Acute Myeloid LeukemiaAdvanced (Inoperable) Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerCervical CancerHIV InfectionsHealthy Adult FemalesSolid Tumours
Phase 1
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
CompletedNCT00432016
Start: 2007-02-28End: 2007-05-31Target: 24Updated: 2007-05-11
Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions
CompletedNCT01330199
Start: 2012-02-29End: 2013-08-31Updated: 2013-09-17
Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer
CompletedNCT01485731
Start: 2012-01-31End: 2015-02-28Updated: 2015-06-03
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
CompletedNCT01900028
Start: 2013-10-31End: 2016-09-30Updated: 2016-10-17
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
CompletedNCT01921140
Start: 2013-09-24End: 2022-03-15Updated: 2022-11-22
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
CompletedNCT01929603
Start: 2013-12-31End: 2016-11-30Updated: 2017-01-16
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
CompletedNCT02093351
Start: 2014-09-01End: 2019-04-29Updated: 2019-10-02
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
CompletedNCT02157883
Start: 2014-11-06End: 2023-05-17Updated: 2025-11-19